MedTrace Logo

Exacerbations Among Patients Receiving Breztri (EROS Study)

NCT06514144 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2409

Last updated 2024-12-13

No results posted yet for this study

Summary

EROS was a retrospective analysis of people with COPD using the MORE2 Registry®. Inclusion required ≥1 severe, ≥2 moderate, or ≥1 moderate exacerbation while on other maintenance treatment. Primary outcomes were the rate of COPD exacerbations and healthcare costs for those that received BGF promptly. The effect of each 30-day delay in initiation of BGF was estimated using a multivariable negative binomial regression model.

Conditions

  • Pulmonary Disease
  • Chronic Obstructive
  • Retrospective Studies

Interventions

DRUG

BGF

budesonide/glycopyrrolate/formoterol fumarate

Sponsors & Collaborators

Principal Investigators

  • Michael Pollack, MS · AstraZeneca

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-01
Primary Completion
2023-03-07
Completion
2023-03-07

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06514144 on ClinicalTrials.gov